Systematic review: cystic fibrosis in the SARS-CoV-2/COVID-19 pandemic
Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the development of life-threatening COVID-19 are believed to disproportionately affect certain at-risk populations. However, it is not clear whether individuals with cystic fibrosis (CF) are at a higher ri...
Main Authors: | Hannah R. Mathew, May Y. Choi, Michael D. Parkins, Marvin J. Fritzler |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-05-01
|
Series: | BMC Pulmonary Medicine |
Online Access: | https://doi.org/10.1186/s12890-021-01528-0 |
Similar Items
-
Cytokine autoantibodies in SARS-CoV-2 prepandemic and intrapandemic samples from an SLE cohort
by: Ann Elaine Clarke, et al.
Published: (2022-12-01) -
Seroprevalence of SARS-CoV-2 IgG in people with cystic fibrosis
by: Kathleen Mahan, et al.
Published: (2024-03-01) -
Crosslink between SARS-CoV-2 replication and cystic fibrosis hallmarks
by: Virginia Lotti, et al.
Published: (2023-05-01) -
Protecting clinical trials in cystic fibrosis during the SARS-CoV-2 pandemic: risks and mitigation measures
by: Silke van Koningsbruggen-Rietschel, et al.
Published: (2021-08-01) -
SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far
by: Carmelo Biondo, et al.
Published: (2022-12-01)